This well-conducted review assessed the effect of bone marrow-derived cell (BMC) transplantation on cardiovascular outcomes in patients with ischaemic heart disease. The authors concluded that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters compared with conventional therapy, and appears to be safe. These conclusions are likely to be reliable.
Study selection Study designs of evaluations included in the review
Randomised controlled trials (RCTs) and cohort studies were eligible for inclusion.
Specific interventions included in the review
Studies of BMC transplantation were eligible for inclusion. Studies of cardiac repair solely through mobilisation of endogenous BMCs with systemic administration of cytokines were excluded. The included studies transplanted a variety of BMC populations by either intracoronary or intramyocardial injection. Studies also varied greatly in the timing of transplantation (between 1 day and 81 months after myocardial infarction (MI) or percutaneous coronary event; median 9.8 days) and the number of cells transplanted. The control interventions were not reported.
Participants included in the review
Studies of patients with IHD were eligible for inclusion. The studies in the review included participants with acute MI and/or ischaemic cardiomyopathy.
Outcomes assessed in the review
Studies reporting cardiovascular outcomes were eligible for inclusion. The outcomes assessed were: change from baseline in mean left ventricular (LV) ejection fraction; infarct scar size; and LV end-systolic volume and LV enddiastolic volume. Follow-up in the included studies ranged from 3 to 18 months (median 4).
How were decisions on the relevance of primary studies made?
Two reviewers working independently assessed the studies in duplicate.
Assessment of study quality
RCTs were assessed using the criteria of Juni et al., which consider methods of randomisation and allocation concealment, group comparability, blinding, loss to follow-up and use of intention-to-treat analysis. A modified Newcastle-Ottawa scale was used to assess cohort studies; this considers selection and comparability of cohorts, ascertainment of exposure, outcome assessment, and length and adequacy of follow-up. Two reviewers independently abstracted quality assessment data, and referred any disagreements that could not be resolved by consensus to a third reviewer.
